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**Twenty-Third International Conference on Antiviral Research**  Sponsored by the  **International Society for Antiviral Research**  **Hyatt Regency San Francisco**San Francisco, California, USA  April 25--April 28, 2010 **Sunday, April 25, 2010Drug Discovery and Development 101**Chair(s): Joe Colacino, Ph.D. and Amy Patick, Ph.D.Grand A  01:00 p.m.--04:00 p.m. 13:001.Nonclinical Toxicology Safety Assessment of Antiviral TherapeuticsAnne ChesterGilead Sciences, USA   13:452.Computational Chemistry in Drug DiscoveryKen Brameld, Ph.D.Roche Palo Alto, LLC USA 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04:45 p.m.--05:00 p.m. 16:45Welcome to the 23rd ICARAmy Patick, Ph.D.President, ISAR   16:50Welcome to San FranciscoJoe Colacino, Ph.D.Chair, ICAR Conference Committee   16:55Introduction of the Keynote SpeakerJoseph Colacino, Ph.D.President-Elect, ISAR  **Keynote Address**Chair(s): Joe Colacino, Ph.D.Grand A  05:00 p.m.--06:00 p.m.4.Recent Progress in the Simplification of HIV Therapy and Future ProspectsJohn MartinGilead Sciences, Inc., USA  **Opening Reception**Atrium 2--5  06:00 p.m.--08:00 p.m.  **Monday, April 26, 2010**  **Oral Session 1: Mini-Symposium: Antiviral Drug Resistance**Chair(s): Samuel Broder, M.D. and Jose Este, Ph.D.Grand A  08:00 a.m.--12:00 p.m. 08:155.Confronting HIV Drug ResistanceDouglas Richman, M.D.University of California at San Diego, USA   09:006.Emergence of Resistance to HCV Direct Acting Antivirals and Potential Therapeutic ImplicationsIsabel Najera, Ph.D.Roche Palo Alto LLC, USA   09:45Break   10:157.Expending the Capability of HIV Drug Resistance Assays to New Drug Targets, HCV, and InfluenzaChristos Petropolous, Ph.D.Monogram Biosciences, Inc., USA   10:458.Next Generation Sequencing Insights into Virus QuasispeciesRobert Shafer, Ph.D.Stanford University, USA   11:159.Influenza Antiviral Resistance: Epidemiologic and Clinical ImplicationsFrederick HaydenUniversity of Virginia, USA; World Health Organization, Switzerland  **Elion Award Lecture**Grand A  01:00 p.m.--02:00 p.m. 13:00Presentation of Elion AwardAmy Patick, Ph.D.President, ISAR   13:1510.Uncommon CombinationsBo Oberg, Ph.D.Medivir AB, Huddinge, Sweden  **Oral Session 2: Hepatitis Viruses**Chair(s): Phillip Furman, Ph.D. and Klaus Klumpp, Ph.D.Grand A  02:00 p.m.--04:00 p.m. 14:0011.Diphenylcarboxamides as Inhibitors of HCV Non-structural Protein NS5A*Malcolm Carter*, Bob Baxter, David Bushnell, Stuart Cockerill, Jo Chapman, Sally Fram, Emma Goulding, Mike Lockyer, Neil Mathews, Pilar Najarro, Dilupa Rupassara, James Salter, Elaine Thomas, Chris Wheelhouse, Jessica Borger, Kenneth PowellArrow Therapeutics, London, United Kingdom   14:1512.Selection of Clinically Relevant Protease Inhibitor Resistant Viruses using the HCV Infection System*Guofeng Cheng*, Katie Chan\@gilead.com, Huiling Yang, Amy Corsa, Maria Pokrovskii, Matthew Paulson, Margaret Robinson, Gina Bahador, Weidong Zhong, William DelaneyGilead Sciences, Foster City, CA, USA   14:3013.*In Vitro* Selection and Characterization of Hepatitis C Virus Replicons Double or Triple Resistant to Various Non-nucleoside HCV Polymerase Inhibitors*Leen Delang*, Inge Vliegen, Pieter Leyssen, Johan NeytsRega Institute for Medical Research, K.U.Leuven, Leuven, Belgium   14:4514.Identification and Characterization of a Hepatitis C Virus Capsid Assembly Inhibitor*Juliane Gentzsch*^1^, Clarence R. Hurt^2^, Vishwanath R. Lingappa^2^, Thomas Pietschmann^11^Division of Experimental Virology, TWINCORE, Hannover, Germany; ^2^Prosetta Bioconformatics, San Francisco, CA, USA   15:0015.The Requirement of HCV NS3 Oligomerization for RNA Helicase Activity is RNA Substrate Dependent*Julie Hang*, Yanli Yang, Junjun Gao, Vincent Leveque, Marie Dinh, Mohammad Hekmat-Nejad, George Stepan, Phil Kobel, Klaus KlumppRoche, Palo Alto, CA, USA   15:1516.Bound Structure and Biochemical Mechanism of Action of BI 201335, A Potent, Non-covalent Inhibitor of HCV NS3-NS4A Protease*Christopher T. Lemke*, Songping Zhao, Nathalie Goudreau, Oliver Hucke, Diane Thibeault, Montse Llinàs-Brunet, Peter W. WhiteBoehringer Ingelheim (Canada) Ltd., Laval, QC, Canada   15:3017.MK-5172, A Novel Macrocyclic Inhibitor of NS3/4A Protease Demonstrates Efficacy against Viral Resistance in the Chimpanzee Model of Chronic Hepatitis C Virus Infection*Steve Ludmerer*^1^, Steve Carroll^2^, John McCauley^3^, Mike Rudd^3^, Paul Coleman^3^, Nigel Liverton^3^, Christine Burlein^2^, Jill DiMuzio^2^, Adam Gates^2^, Don Graham^1^, Carolyn McHale^1^, Mark Stahlhut^2^, Christine Fandozzi^4^, Daria Hazuda^2^, Joe Vacca^1^, David Olsen^21^Department of Antiviral Research, Merck-Frosst Research Laboratories, Kirkland, QC, Canada; ^2^Department of Antiviral Research, Merck Research Labs, West Point, PA, USA; ^3^Department of Medicinal Chemistry, Merck Research Labs, West Point, PA, USA; ^4^Department of Drug Metabolism, Merck Research Labs, West Point, PA, USA   15:4518.Late Breaker Presentation  **Tuesday, April 27, 2010**  **Prusoff Young Investigator Award Lecture**Grand A  08:00 a.m.--09:00 a.m. 08:00Presentation of Prusoff AwardAmy Patick, Ph.D.President, ISAR   08:1519.Coreceptors and Cellular Factors as Targets for Antiviral DrugsJose Este, Ph.D.Fundacio Irsicaixa, Barcelona, Spain  **Oral Session 3: Retroviruses and Herpesviruses**Chair(s): Rhonda Cardin, Ph.D. and Masanori Baba, Ph.D.Grand A  09:00 a.m.--11:30 a.m. 09:0020.Identification of a N-linked Glycan on HIV-1 gp120 that is Indispensable for Viral Entry*Katrien François*, Jan BalzariniRega Institute for Medical Research, K.U.Leuven, B-3000 Leuven, Belgium   09:1521.Protein--Protein Interactions Occurring during HIV Capsid Assembly in a Cell-free Protein Synthesizing System*Kiel Copeland*^1^, William Hansen^1^, Vinod Asundi^1^, Shi Hong^1^, James Chamberlin^1^, Debendranath Dey^1^, Sean Broce^1^, Harold Himmel^1^, Caleb Decloutte^1^, Salvin Ram^1^, Imke Steffen^2^, Stefan Pöhlmann^2^, Jaisri R. Lingappa^3^, Clarence R. Hurt^1^, Vishwanath R. Lingappa^11^Prosetta Bioconformatics, Inc., San Francisco, CA, USA; ^2^Institute of Virology Hannover Medical School, Hannover, Germany; ^3^Deptartment of Global Health, University of Washington, Seattle, WA, USA   09:30Break   10:0022.An Intrabody based on a Llama Single-Domain Antibody Targeting the N-terminal α-Helical Multimerization Domain of HIV-1 Rev Inhibits Viral Replication*Dirk Daelemans*^1^, Thomas Vercruysse^1^, Els Pardon^2^, Els Vanstreels^1^, Jan Steyaert^21^Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium; ^2^Structural Biology Brussels, Department of Molecular Interactions, VUB, Brussels, Belgium   10:1523.Discovery of GS-9350: A Novel and Selective Pharmacoenhancer without Anti-HIV Activity*L. Xu*, H. Liu, B. Murray, C. Callebaut, A. Hong, R. Vivian, M. Lee, L. Tsai, K. Stray, J. Chau, R. Strickley, J. Koziara, Y. Choi, G. Rhodes, M. DesaiGilead Sciences, Foster City, CA, USA   10:3024.Protection against Genital HSV-2 in Guinea Pigs with Subunit Vaccines Containing gD2, gB2, and gH/gL glycoprotein antigens complexed with CLDC Adjuvant*R.D. Cardin*^1^, F.J. Bravo^1^, J.D. Earwood^1^, J.R. Clark^1^, R.J. Eisenberg^2^, G.H. Cohen^2^, J. Fairman^3^, D.I. Bernstein^11^Cincinnati Children\'s Hosp, Cincinnati, OH, USA; ^2^Univ. of Penn, Philadelphia, PA, USA; ^3^Juvaris BioTherapeutics, Inc., Pleasanton, CA, USA   10:4525.*In Vitro* and *In Vivo* Activities of the Novel Anti-Cytomegalovirus Compound AIC246*Peter Lischka*^1^, Guy Hewlett^2^, Tobias Wunberg^3^, Judith Baumeister^4^, Daniela Paulsen^1^, Thomas Goldner^1^, Helga Ruebsamen-Schaeff^1^, Holger Zimmermann^11^AiCuris GmbH&Co.KG, Wuppertal, Germany; ^2^HBSC, Wuppertal, Germany; ^3^Boehringer Ingelheim RCV GmbH&CoKG, Vienna, Austria; ^4^Ablynx N.V., Zwijnaarde-Gent, Belgium   11:0026.A Chimeric Guinea Pig Cytomegalovirus (GPCMV) Encoding Wild Type or Mutant HCMV UL97 Renders GPCMV Susceptible or Resistant to Ganciclovir while Retaining an Ability to Disseminate in the Animal Host*Alistair McGregor*, Jared Leibelt, Catherine Bouska, Mark SchleissUniversity of Minnesota, Minneapolis, MN, USA   11:1527.Late Breaker Presentation  **Clinical Symposium**Chair(s): Paul Griffiths, M.D. and Richard Whitley, M.D.Grand A  01:00 p.m.--04:00 p.m.  **Reception**Grand Foyer  07:00 p.m.--07:30 p.m.  **ICAR Banquet and Program**Grand A  07:30 p.m.--09:30 p.m.  **Wednesday, April 28, 2010Oral Session 4: Mini-Symposium: Prodrug Chemistry and Antiviral Drug Development**Chair(s): Karl Y. Hostetler, M.D. and Adrian S. Ray, Ph.D.Grand A  08:00 a.m.--12:00 p.m. 08:0028.IDX-184---A Novel, Liver-targeted, Once-A-Day Nucleotide Prodrug for the Treatment of Chronic HCV InfectionDavid Standring, Ph.D.Idenix, Inc., USA   08:3029.CMX157: Design and Development of Hexadecyloxypropyl Cidofovir and TenofovirRandall Lanier, Ph.D.Chimerix, Inc., USA   09:0030.Altering the Chemistry of Alkoxyalkyl Prodrugs of Acyclic Nucleoside Phosphonates: New Directions and Novel ApplicationsKarl HostetlerUniversity of California at San Diego, USA  09:30Break   10:0031.Nucleoside Phosphonate Prodrugs: From Improved Oral Bioavailability to Target Tissue EnrichmentAdrian RayGilead Sciences, Inc., USA   10:3032.PSI-7851: From Discovery to the ClinicPhillip FurmanPharmasset, Inc., USA   11:0033.Breaking the Rules: Selection of a Prodrug Clinical Candidate for HCV TherapyGeoff Henson, Ph.D.Inhibitex, Inc., USA  **Oral Session 5: Respiratory Viruses, Emerging Viruses and Biodefense**Chair(s): Graciela Andrei, Ph.D. and Peter Silvera, Ph.D.Grand A  01:00 p.m.--05:30 p.m. 13:0034.PLENARY: Celebrating AZT! Antiretroviral Drugs: From Bench to Bedside to the World.Samual Broder, M.D.Celera Genomics, Inc., USA   13:4535.ST-246, A Therapeutic for Smallpox*Tahar Babas*^1^, Deborah Sites^1^, Lourdes Nieves-Duran^1^, Amy Sands^1^, Rhonda Wright^1^, Amy Rippeon^1^, Dawn Golightly^1^, Ginger Donnelly^1^, Lowrey Rhodes^1^, Robert Jordan^2^, Dennis Hruby^2^, Peter Silvera^11^Southern Research Institute, Frederick, MD, USA; ^2^SIGA Technologies, Corvalis, OR, USA   14:0036.Evidence for Host Drug Targets Essential for Dengue Virus Capsid Formation.*Marissa Baker-Wagner*^1^, Nicole Wolcott^2^, Yoko Marwidi^1^, Shao Feng Yu^1^, Debendranath Dey^1^, Bruce Onisko^1^, Katie Barlow^1^, Shalini Potluri^1^, Christine Sahlman^1^, Alfredo Calayag^1^, Vishwanath R. Lingappa^1^, Pamela Glass^3^, Michael Farmer^1^, Clarence R. Hurt^1^, William Hansen^11^Prosetta Bioconformatics, Inc., San Francisco, CA, USA; ^2^CUBRC, Inc., Buffalo, NY, USA; ^3^Virology Division, USAMRIID, Ft Detrick, MD, USA   14:1537.An Adenosine Nucleoside Inhibitor of Dengue Virus.*Wouter Schul*, Yen-Liang Chen, Zheng Yin, Thomas Keller, Pei-Yong ShiNovartis Institute for Tropical Diseases, Singapore, Singapore   14:3038.Small Molecule Agonists of the RIG-I Pathway and their Potent Antiviral Actions*Kristin Bedard*^1^, Nicholas Pointinger^1^, Eric Tarcha^1^, Michael Katze^2^, Michael Gale Jr.^2^, Shawn Iadonato^11^Kineta, Inc., Seattle, WA, USA; ^2^University of Washington, Seattle, WA, USA   14:4539.The NF-KappaB-Inhibitor SC75741 Efficiently Blocks Influenza Virus Propagation by Retention of the Viral RNP Complexes in the Nucleus without the Tendency to Induce Resistant Virus Variants*Christina Erhardt*^1^, Andrea Rückle^1^, Karoline Droebner^2^, Eike Hrincius^1^, Oliver Planz^2^, Stephan Ludwig^11^FLI, Tuebingen, Germany; ^2^IMV/ZMBE, Muenster, Germany   15:0040.The Triple Combination Antiviral Drug (TCAD) Regimen of Amantadine, Ribavirin, and Oseltamivir is Highly Efficacious Against Susceptible and Resistant Influenza Virus Strains in Mouse Treatment Models*Matthew Gross*^1^, Minh Le^1^, Donald Smee^2^, Dale Barnard^2^, Amy Patick^1^, Jack Nguyen^11^Adamas Pharmaceuticals, Emeryville, CA, USA; ^2^Utah State University, Logan, UT, USA   15:1541.*In Vitro* and *In Vivo* Efficacy of Combinational Therapy with Favipiravir (T-705) and Oseltamivir against Influenza A/CA/04/09 Pandemic H1N1 Virus*Dale Barnard*^1^, Yousuke Furuta^2^, Klaus Klummp^3^, Donald Smee^1^, John Morrey^1^, Bart Tarbet^11^Institute for Antiviral Research, Utah State University, Logan, UT, USA; ^2^Toyama Chemical Co., Ltd., Tokyo, Japan; ^3^Roche Palo Alto LLC, Palo Alto, CA, USA,   15:30Invitation to 24th ICAR, Sofia, BulgariaAngel Galabov, Ph.D.Host, 24th ICAR   15:45ISAR Business Meeting   16:00Break   16:1542.Antiviral Activity of Leflunomide against Respiratory Syncytial Virus*Melinda Dunn*, Deborah Knight, W. James WaldmanDepartment of Pathology, The Ohio State University, Columbus, OH, USA   16:3043.Small-molecule Inhibition of Respiratory Syncytial Virus Fusion: It takes Two to Tango*Dirk Roymans*^1^, Eric Arnoult^2^, Maxwell D. Cummings^1^, Anil Koul^3^, Koen Andries^41^Tibotec-Virco Virology BVBA, Mechelen, Belgium; ^2^Tibotec, A Division of Janssen-Cilag, Val de Reuil Cedex, France; ^3^Tibotec-Virco Virology BVBA, Beerse, Belgium; ^4^J&JPRD, Beerse, Belgium   16:4544.Enterovirus 3C Proteases: Structure-based Discovery of InhibitorsRolf HilgenfeldUniversity of Luebeck, Luebeck, Germany   17:0045.A Novel 9-Arylpurine Acts as a Selective Inhibitor of *In vitro* Enterovirus Replication Possibly by Targeting Virus Encapsidation*Hendrik Jan Thibaut*^1^, Lonneke van der Linden^2^, Jan Paeshuyse^1^, Armando De Palma^1^, Leire Aguado^3^, Frank Van Kuppeveld^2^, María-Jesús Pérez-Pérez^3^, Johan Neyts^11^Rega Institute for Medical Research, K.U. Leuven, Leuven, Belgium; ^2^Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, Nijmegen Centre for Molecular Life Sciences, Nijmegen, Netherlands; ^3^Instituto de Química Médica (CSIC), Madrid, Spain   17:1546.Is the Large T Antigen: A Target for the Inhibition of SV40 Replication?*Dimitri Topalis*, Ilya Lebeau, Pierre Fiten, Ghislain Opdenakker, Graciela Andrei, Robert SnoeckRega Institute for Medical Research, Leuven, Belgium  **Poster Session 3: Shotgun Poster Presentations**Chair(s): Mark Prichard, Ph.D. and Johan Neyts, Ph.D.Grand A  05:30 p.m.--06:30 p.m.  **Monday, April 26, 2010**  **Poster Session 1: Retroviruses, Hepatitis Viruses, Respiratory Viruses, Emerging Viruses, and Antiviral Methods**Pacific D-O  04:00 p.m.--06:00 p.m.47.Studies of HIV-1 Integrase Inhibitory Activity of *Wrightia tinctoriaPeriyasamy Selvam*^1^, Kasthuraiah Maddali^2^, Yves Pommier^21^Devaki Amma Memorial College of Pharmacy, Chelembra, Malapuram, India; ^2^Laboratory of Molecular Pharmacology, National Cancer Institute, NIH, Bethesda, Maryland 20892, MD, USA  48.Preliminary Evidence of Rapid HBsAg Seroconversion in Patients with Chronic Hepatitis B (CHB) Treated with a DNA-based Amphipathic Polymer*Mamun Al-Mahtab*^1^, Michel Bazinet^2^, Andrew Vaillant^21^Sheikh Mujib Medical University, Dhaka, Bangladesh; ^2^REPLICor Inc., Montreal, QC, Canada  49.γ-Carboline Derivatives as Potent and Selective Inhibitors of Bovine Viral Diarrhea Virus (BVDV) Replication.*Masanori Baba*^1^, Mohammed Salim^1^, Mika Okamoto^1^, Hiroshi Aoyama^2^, Yuichi Hashimoto^2^, Yutaka Takebe^3^, Jan Paeshuyse^4^, Johan Neyts^41^Kagoshima University, Kagoshima, Japan; ^2^The University of Tokyo, Tokyo, Japan; ^3^National Institute of Infectious Diseases, Tokyo, Japan; ^4^Katholieke Universiteit Leuven, Leuven, Belgium  50.Combination of Peramivir and Rimantadine Demonstrate Synergistic Interaction in Influenza A Mouse Model*Shanta Bantia*, Debra Kellogg, Cynthia Parker, YuHong Luo, Y.S. BabuBioCryst Pharmaceuticals, Inc., Birmingham, AL, USA  51.A Single Intramuscular Injection of Peramivir Demonstrates Anti-influenza Activity against Recently Isolated Pandemic Flu Virus H1N1 (A/CA/04/2009)*Shanta Bantia*^1^, Debra Kellogg^1^, Cynthia Parker^1^, Ramanda Upshaw^1^, Natalia Ilyushina^2^, Mark Prichard^3^, Y.S. Babu^11^BioCryst Pharmaceuticals, Inc., Birmingham, AL, USA; ^2^St. Jude\'s Children\'s Research Hospital, Memphis, TN, USA; ^3^University of Alabama at Birmingham, Birmingham, AL, USA  52.*In Vitro* Dose Ranging Studies for Serine Protease Inhibitor, MK-4519, against a Hepatitis C Virus (HCV) Replicon using the BelloCell System*Ashley N. Brown*^1^, D.V. Singer^1^, J.J. McSharry^1^, R.J.O. Barnard^2^, D.J. Hazuda^2^, G.L. Drusano^11^Ordway Research Institute, Albany, NY, USA; ^2^Merck Research Labs, West Point, PA, USA  53.Maporal Hantavirus β-Integrin Utilization and Sensitivity to Favipiravir*Kristin Buys*^1^, Kie-Hoon Jung^1^, Yousuke Furuta^2^, Brian Gowen^11^Institute for Antiviral Research and Department of Animal, Dairy, and Veterinary Sciences at Utah State University, Logan, UT, USA; ^2^Research Laboratories, Toyama Chemical Company, Ltd., Toyama, Japan  54.Small Molecule Inhibitors of Dengue Virus Replication are Active *In VivoChelsea Byrd*, Chris Harver, Kara Cardwell, Doug Grosenbach, Aklile Berhanu, Dongcheng Dai, Dennis Hruby, Robert JordanSIGA Technologies, Corvallis, OR, USA  55.Biological Profiling of GS-9350, A Novel Pharmacoenhancer that Lacks Anti-HIV Activity and Exhibits Low Potential for Metabolic Adverse Effects *In VitroChristian Callebaut*, Luong Tsai, Kirsten Stray, Hongtao Liu, Lianhong Xu, Manoj Desai, Tomas CihlarGilead Sciences, Foster City, CA, USA  56.Production and Characterization of a Highly Infectious Genotype 1B/2A Chimeric Hepatitis C Virus in Cell Culture*Katie Chan*, Huiling Yang, Guofeng Cheng, Maria Pokrovskii, Matthew Paulson, Andrew Greenstein, Hongmei Ho, William DelaneyGilead Sciences, Inc., Foster City, CA, USA  57.Excision of HIV-1 Proviral DNA Using Tre-recombinase: An Experimental Update*Jan Chemnitz*^1^, Patrick Ziegler^2^, Ilona Hauber^1^, Claus-Henning Nagel^1^, Helga Hofmann-Sieber^1^, Markus Manz^3^, Frank Buchholz^4^, Joachim Hauber^11^Heinrich-Pette-Institute for Experimental Virology and Immunology, Hamburg, Germany; ^2^Institute for Research in Biomedicine, Bellinzona, Switzerland; ^3^University Hospital Zurich, Zurich, Switzerland; ^4^Max-Planck-Institute for Molecular Cell Biology and Genetics, Dresden, Germany  58.Small Molecules Targeting Protein--Protein Interactions: A Promising Anti-HIV Strategy*Alba Chimirri*^1^, Laura De Luca^1^, Stefania Ferro^1^, Rosaria Gitto^1^, Anna Maria Monforte^1^, Stefano Agnello^1^, Maria Letizia Barreca^2^, Frauke Christ^3^, Zeger Debyser^31^Department of Medicinal Chemistry, University of Messina, Messina, Italy; ^2^Department of Pharmaceutical Chemistry and Technology, University of Perugia, Perugia, Italy; ^3^Mol. Virology and Gene Therapy Mol. Medicine, Katholieke Universiteit Leuven and IRC KULAK, Leuven, Belgium  59.A Cell Protection Screen Reveals Potent Inhibitors of Multiple Stages of the Hepatitis C Virus Life Cycle*Karuppiah Chockalingam*^1^, Rudo Simeon^1^, Charles Rice^2^, Zhilei Chen^11^Texas A&M University, College Station, TX, USA; ^2^Rockefeller University, New York City, NY, USA  60.Synthesis and Tissue Distribution Studies of Acyloxyalkyl Prodrug Derivative of an Anti-HBV Dinucleotide*John Coughlin*^1^, Kathleen O'Loughlin^2^, Sung Rhee^2^, Mary Tanga^2^, Radhakrishnan Iyer^1^, Anna Furimsky^2^, Seetharamaiyer Padmanabhan^1^, Judith Marquis^3^, Amy Ta^2^, Carol Green^2^, Jon Mirsalis^21^Spring Bank Pharmaceuticals, Inc., Milford, MA, USA; ^2^SRI International, Menlo Park, CA, USA; ^3^Genzyme Corporation, Cambridge, MA, USA  61.CYSTUS052, A New Compound against Seasonal and Pandemic Influenza Virus*Karolin Droebner*^1^, Christina Ehrhardt^2^, Stephan Ludwig^2^, Oliver Planz^11^Friedrich-Loeffler-Institut, Institute of Immunology, Tübingen, Germany; ^2^Institute of Molecular Virology (IMV), University of Münster, Münster, Germany 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